ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Learn about comparative gene expression studies in Alzheimer's disease and other conditions in Mayo Clinic's Precision Medicine in Neurodegeneration Lab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results